

# Correction: Emerging aspects in the regulation of ferroptosis

Helene Nehring, Svenja Meierjohann and Jose Pedro Friedmann Angeli

*Biochem. Soc. Trans.* (2020) 48 (5): 2253–2259 DOI: <https://doi.org/10.1042/BST20200523>

The authors of this paper would like to make the following correction to the citations within the text:

Reference 48 was a duplication of reference 12 and should have instead cited Bersuker, K., Hendricks, J.M., Li, Z. et al. (2019) The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis *Nature* 575, 688–692. DOI: [10.1038/s41586-019-1705-2](https://doi.org/10.1038/s41586-019-1705-2)

## In the section entitled “The FSP1 ubiquinone system”

The FSP1-ubiquinone axis was then characterized as a GSH/GPX4 independent ferroptosis-suppressing pathway that exemplifies an elegant system for the enzymatic regeneration of endogenous antioxidants [47].

Should instead cite the following:

The FSP1-ubiquinone axis was then characterized as a GSH/GPX4 independent ferroptosis-suppressing pathway that exemplifies an elegant system for the enzymatic regeneration of endogenous antioxidants [47, 48].

## In the section entitled “The tetrahydrobiopterin-DHFR system”

More recently, another novel endogenous antioxidant system has been identified. Using CRISPR activation screens, a study identified tetrahydrobiopterin (BH4) as an essential metabolite supporting the proliferation of cancer cell lines challenged with the GPX4 inhibitor RSL3 [48].

Should have cited

More recently, another novel endogenous antioxidant system has been identified. Using CRISPR activation screens, a study identified tetrahydrobiopterin (BH4) as an essential metabolite supporting the proliferation of cancer cell lines challenged with the GPX4 inhibitor RSL3 [11, 12].

## At the end of the article, the final sentence

Hence, these studies demonstrate that DHFR should be regarded as an important regulator of ferroptosis, while its inhibitor methotrexate, a common chemotherapeutic agent, could be a promising therapeutic option for ferroptotic anti-cancer therapies [48]

Should have read

Hence, these studies demonstrate that DHFR should be regarded as an important regulator of ferroptosis, while its inhibitor methotrexate, a common chemotherapeutic agent, could be a promising therapeutic option for ferroptotic anti-cancer therapies [12].

Correction published:  
18 December 2020